Advertisement
U.S. markets open in 2 hours 33 minutes
  • S&P Futures

    5,305.50
    -2.75 (-0.05%)
     
  • Dow Futures

    40,141.00
    -3.00 (-0.01%)
     
  • Nasdaq Futures

    18,492.75
    -11.00 (-0.06%)
     
  • Russell 2000 Futures

    2,136.60
    -1.80 (-0.08%)
     
  • Crude Oil

    82.11
    +0.76 (+0.93%)
     
  • Gold

    2,231.90
    +19.20 (+0.87%)
     
  • Silver

    24.83
    +0.08 (+0.32%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.99
    +0.21 (+1.64%)
     
  • GBP/USD

    1.2617
    -0.0021 (-0.17%)
     
  • USD/JPY

    151.3960
    +0.1500 (+0.10%)
     
  • Bitcoin USD

    70,638.84
    +523.54 (+0.75%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,954.76
    +22.78 (+0.29%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Drug pricing review group raises recommended price for Gilead's remdesivir

June 24 (Reuters) - The Institute for Clinical and Economic Review on Wednesday boosted its benchmark price for Gilead Sciences Inc's remdesivir, suggesting the antiviral could be priced up to $5,080, based on benefits shown in COVID-19 patients.

The Boston-based group had previously suggested a price of around $4,500 for a 10-day course of remdesivir. Gilead has not announced the price of the therapy in the United States. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)

Advertisement